section name header

Pronunciation ⬇

se-VIM-e-leen

Classifications ⬆ ⬇

Therapeutic Classification: xerostomia therapy adjuncts

Pharmacologic Classification: cholinergics, muscarinic agonists, sialagogues

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Direct cholinergic (muscarinic) effects result on increased secretion of exocrine glands including salivary and sweat glands, and increased smooth muscle tone in the gastrointestinal and urinary tracts.
Therapeutic effects:
  • Improved symptoms of dry mouth in patients with Sjögren's syndrome.

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly absorbed following oral administration.

Distribution: Extensively bound to tissues.

Metabolism/Excretion: Mostly metabolized by the liver (CYP2D6 and CYP3A3/4 isoenzymes) (the CYP2D6 enzyme system exhibits genetic polymorphism; ~7% of population may be poor metabolizers and may have significantly ↑ cevimeline concentrations and an ↑ risk of adverse effects); 16% excreted unchanged in urine.

Half-Life: 5 hr.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
POunknown1.5–2 hrunknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: excessive sweating, hot flashes

EENT: rhinitis, visual disturbances

GI: nausea, diarrhea, excessive salivation

Neuro: coughing

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Evoxac

Code ⬆

NDC Code